NanoEntek Launches EVE-HT A26, a Fully Automated High-Throughput Cell Counter for the Global CDMO Market

Delivers a 100% automated workflow from sample preparation to analysis, resolving bottlenecks in large-scale bioprocessing

CA, UNITED STATES, July 14, 2026 /EINPresswire.com/ --  Delivers a 100% automated workflow from sample preparation to analysis, resolving bottlenecks in large-scale bioprocessing
 Building on supply references with leading global biopharma companies to expand market reach amid growing demand in the CGT sector

NanoEntek has launched EVE-HT A26, a fully automated high-throughput cell counter, marking the company’s strategic expansion into the global bioprocessing and CDMO (Contract Development and Manufacturing Organization) market.

Built on the advanced core technology of NanoEntek’s EVE-HT series, EVE-HT A26 is a next-generation platform that automates the entire workflow — from cell preparation and staining to counting and analysis. The system features a 7-axis robotic architecture that integrates NanoEntek’s proprietary Bio-MEMS technology with linear motor drives and precision robotic pipetting, delivering exceptional throughput, accuracy, and ease of use in a single instrument.

EVE-HT A26 stands out for its ultra-fast processing speed and exceptional sample efficiency. The system processes up to 96 samples in just 10 minutes — fully unattended, from staining through analysis — compared with the more than three hours typically required by competing systems. Unlike competing instruments that require 170 μL or more per test, EVE-HT A26 delivers high-precision analysis with as little as 20 μL, translating into significant cost savings and improved yield for research and production environments working with high-value cell types.

"EVE-HT A26 represents the next generation of cell counting technology, combining exceptional speed, precision, and fully integrated automation in a single platform," said a NanoEntek official. "We expect EVE-HT A26 to maximize operational efficiency and bring a paradigm shift to cell counting workflows at CDMOs and biopharmaceutical research and manufacturing facilities worldwide."

Amy Kim
Nano Entek
amy@nanoentek.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.